Lexaria Bioscience Corp 2024年度报告

(Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year endedAugust 31, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [____] to [____] Commission file number001-39874 Lexaria Bioscience Corp. 20-2000871(I.R.S. EmployerIdentification No.) V1X 2P7(Zip Code) Registrant’s Telephone number, including area code:250-765-6424 N/A (Title of class) Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act Yes☐No☒ Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller Large accelerated filerNon-accelerated filer If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant period pursuant to §240.10D-1(b)☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐ As of February 28, 2025, the last day of the registrant’s most recently completed second fiscal quarter, the aggregate market value ofthe common stock held by non-affiliates of the registrant was approximately $24.6 million, based on the closing price of the Indicate the number of shares outstanding of each of the registrant’s classes of common stock as of the latest practicable date. 22,225,846 common shares as of November 25, 2025. DOCUMENTS INCORPORATED BY REFERENCE None. Table of Contents Cautionary Note Regarding Forward-Looking Statements This Annual Report on Form 10-K (“this report”) contains forward-looking statements as that term is defined in the Private SecuritiesLitigation Reform Act of 1995. Any statements contained herein that are not statements of historical fact may be forward-lookingstatements relating to future events or our future financial performance and are based on our present beliefs, assumptions, andinformation currently available to us. In some cases, forward-looking statements can be identified by terminology such as “may”, These statements contain predictions and involve known and unknown risks, including the risks in the section entitled “Risk Factors”set forth in Item 1(A) in this report, uncertainties and other factors that may cause our or our industry’s levels of activity, performance,achievements, or actual results to be materially different from any future levels of activity, performance, achievements, or results Forward-looking statements in this report include statements about, among other things: the status, progress and results of ourresearch programs; our ability to obtain regulatory approvals for, and the level of market opportunity for, our product candidates; ourbusiness plans, strategies and objectives, including plans to pursue collaboration, licensing or other similar arrangements ortransactions; our expectations regarding our liquidity and performance, including our expense levels, sources of capital and ability to We caution placing undue reliance on any forward-looking statements as they speak only as of the date on which such statements weremade, and we do not assume any obligation to update any forward-looking statement or to reflect the occurrence of an unanticipatedevent. New factors may emerge, and it is not possible to predict all factors that may affect our business and prospects.